UNIVERSITY *of*York

This is a repository copy of *Model-driven Experimentation: A new approach to understand mechanisms of tertiary lymphoid tissue formation, function and therapeutic resolution.*.

White Rose
university consortium
Universities of Leeds, Sheffield & York

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

Model-driven Experimentation: A new approach to understand mechanisms of tertiary lymphoid tissue formation, function and therapeutic resolution.

James A. Butler[1], Jason Cosgrove[1], Kieran Alden[2], Jonathan Timmis[2], Mark C. Coles[1*]

[1]Biology, University of York, United Kingdom, [2]Electronics, University of York, United Kingdom

This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

Model-driven Experimentation: A new approach to understand mechanisms of tertiary lymphoid tissue formation, function and therapeutic resolution.

James Butler[1,2,3]*, Jason Cosgrove[1,2,3]*, Kieran Alden[2,3], Jon Timmis[2,3], Mark Coles[1,3]

1. Centre for Immunology and Infection, Department of Biology and Hull York Medical School
2. Department of Electronics
3. York Computational Immunology Laboratory, University of York, York, UK, YO10 5DD, United Kingdom

* co-first authors

Correspondence:
Mark Coles (mark.coles@york.ac.uk)

37   **Abstract:**

38

39   The molecular and cellular processes driving the formation of secondary lymphoid tissues have

40   been extensively studied using a combination of mouse knockouts, lineage specific reporter

41   mice, gene expression analysis, immunohistochemistry and flow cytometry. However, the

42   mechanisms driving the formation and function of tertiary lymphoid tissue (TLT) experimental

43   techniques have proven to be more enigmatic and controversial due to differences between

44   experimental models and human disease pathology. Systems-based approaches including data-

45   driven biological network analysis (Gene Interaction Network, Metabolic Pathway Network,

46   Cell-Cell signalling & cascade networks) and mechanistic modelling afford a novel perspective

47   from which to understand TLT formation and identify mechanisms that may lead to the

48   resolution of tissue pathology. In this perspective, we make the case for applying model-driven

49   experimentation using two case studies which combined simulations with experiments to

50   identify mechanisms driving lymphoid tissue formation and function, and then discuss

51   potential applications of this experimental paradigm to identify novel therapeutic targets for

52   TLT pathology.

53

54

55

Formation and function of secondary and tertiary immune microenvironments

Lymphoid tissues are responsible for the orchestration of functional immune responses. This is achieved through the development and maintenance of niches that support the retention, activation and proliferation of adaptive immune cells in response to antigenic stimulation. Adult lymphoid tissue architecture is organised by an underlying network of stromal cells that produce extracellular matrix (e.g. collagens) and provide survival (e.g. BAFF, IL-7), migratory (CCL19/21, CXCL13) and immune activation (the storage and presentation of immune complexes by follicular dendritic cells) signals (Junt et al, 2008). Distinct stromal subsets with unique secretion profiles (chemokines, other cytokines, survival factors) develop in response to signalling from lymphocytes with a key role for TNF superfamily receptors; this stromal-lymphocyte cross-talk ensures the correct cell type is stimulated (or regulated) at the right time and place. Sustained cross-talk between mesenchymal stroma and lymphocyte subsets is a core feature of lymphoid tissue formation and maintenance, and occurs irrespective of the tissue type or anatomical location.

Formation of lymphoid tissues can occur by different cellular and molecular mechanisms. During foetal development secondary lymphoid tissues form in a process dependent on the RAR-related orphan receptor gamma, RORγ transcription factor expressing lymphoid tissue inducer cells (LTi) responding to localised chemotactic gradients leading to formation of lymph nodes (LN) and Peyer's patches (PP) in a lymphotoxin β (LTβ) dependent process (Pavert & Mebius, 2010). Localised mesenchyme, lymphoid tissue organiser (LTo) cells differentiate into adult marginal reticular cells (MRCs), fibroblastic reticular cells (FRCs) and follicular dendritic cells (FDCs) (Jarjour et al., 2014). Likewise, in the adult, innate lymphoid cells type 3 (ILC3s), the adult equivalent of LTi cells, have a key role in regulating crypto-patches that

81 can mature into isolated lymphoid follicles (Mowat and Agace, 2014). These specialised

82 lymphoid structures contain predominantly B cells and often contain germinal centre (GC)

83 reactions.

84

85 In humans, tertiary lymphoid tissues (TLT) are found in inflammatory immune responses

86 associated with chronic pathology from hip joint replacements, keloids, tissues in autoimmune

87 disease (e.g. the salivary gland in Sjogren's syndrome, multiple sclerosis and rheumatoid

88 arthritis) to solid tumours and follicular lymphomas in the bone marrow (Mittal et al., 2013;

89 Bombardieri et al., 2012; Bagabir et al., 2012; Dieu-Nosjean et al., 2016; Guilloton et al.,

90 2012). Although the role of specific cell types has been controversial, there is an emerging

91 paradigm of a multi-step process where localised inflammation induces stromal cell activation

92 in a lymphocyte independent process, leading to localised microenvironments permissive for

93 T and B cells entry (De Silva & Klein, 2015). These lymphocytes have the potential to drive

94 the formation of organised tertiary tissue in an autocrine dependent process. This process

95 closely resembles the capacity of naïve B cells to drive B cell follicle formation in secondary

96 lymphoid tissues in a TNFα and LTβ dependent process, and the capacity of activated B cells

97 to generate the germinal center (GC), a transient microenvironment that drives high affinity

98 immune responses in a self-regulating autocrine dependent process. In both secondary immune

99 tissues (LN, PP and spleen) and tertiary lymphoid tissues including ILFs and TLT, activated B

100 cells prime the formation of the GC reaction. This specialised microenvironment contains both

101 activated and proliferating B cells and different stromal compartments of CXCL12 secreting

102 stroma (dark zone) and CXCL13 secreting FDCs (light zone). This facilitates the cyclic

103 selection and expansion of antigen specific B cells (Zhang et al., 2016).

104

Non-lymphoid inflammatory immune structures, granulomas, can form in the liver, intestine, adipose tissue (crown-like structures) and lung induced by chronic infection/inflammation associated with tuberculosis, leishmaniasis, schistosomiasis, cell death and Crohn's disease (Sandor et al., 2003; Beattie and Kaye, 2016; Bolus et al., 2015). The formation of these highly dynamic microenvironments superficially resemble TLT, however their formation and organisation is driven by activated macrophages rather than by the mesenchymal-lymphocyte cross-talk observed in lymphoid tissues thus do not exhibit lymphocyte compartmentalisation. Granuloma structures are very heterogeneous in presentation within individual patients in a continuum between early macrophage centric granulomas, self-resolving granulomas to fibroblastic structures, these often being fibrotic rather than taking on a supportive stromal network phenotype. The triggers that drive granuloma formation instead of TLT formation appear not to be due to differences in the different chemotactic cues delivered by activated macrophages compared to those delivered by activated stromal fibroblasts leading to a very different cellular make up to the inflammatory foci of leukocytes (primarily myelo-monocytic (granuloma) vs. lymphocytic (TLT)).

Current approaches to studying lymphoid tissue formation: Limits, challenges ad new approaches.

Experimental studies, principally performed in gene knockout, lineage specific fluorescent protein and Cre reporter mouse lines have contributed significant insights into the roles of multiple different cell types and molecules in lymphoid tissue formation and function. This has been further validated using histology and flow cytometry analysis on human secondary lymphoid tissues. However, in contrast to secondary lymphoid tissues there are some distinct differences in human tissue pathologies to those found in mice including the cellular

130   composition of TLTs, granulomas and other inflammatory tissues. This arises in part from

131   genetic and physiological differences between human and mice including the timing and

132   duration of the immune response (chronic vs acute inflammation), the inflammatory triggers

133   (infection, autoimmunity and cancer) and transcriptional differences in immune cells in the

134   different species. In general, mouse models of immune mediated inflammatory disease are

135   acute and fail to replicate the chronic human disease characterised by disease flairs followed

136   by remission, limiting their translational capacity to human disease. Infection and tumour

137   models in mice either rapidly resolve (too quickly for chronic pathology to establish) or lead

138   to the mouse having to by euthanized for health and welfare prior to tertiary lymphoid

139   pathology occurring. In comparison, humans may live the rest of their life with the disease

140   pathology, particularly in the context of treatment with biologics and small molecules, thus

141   pathology has the opportunity to evolve from localised inflammation to fibrotic tissue failure,

142   systemic inflammation and autoimmunity working together to prevent disease resolution.

143   Increasingly human 3-dimensional tissue culture models containing both stroma and

144   lymphocytes have become increasingly common and useful in understanding underlying

145   molecule mechanisms of TLT formation. However, it is not currently possible to represent the

146   full complexity of chronic human pathology *in vitro*.

147

148   Experimental systems (*in vivo* and *in vitro*) to date have proven limited in their ability to explain

149   chronic clinical pathology and resolve established Sjogren's pathology, although TNF has an

150   important role in FDC differentiation and B cell organisation, anti-TNF fails to induce

151   resolution disease (Sankar, 2004). To better understand the form and function of TLTs, current

152   knowledge of stromal regulation through molecular signals and immune cell behaviour within

153   lymphoid tissue must be consolidated and considered in a quantitative, systems-based

154   approach. The development of systems-level stochastic computational models can bring

together a broad understanding across spatiotemporal scales of how genetic and molecular factors relate to cellular and tissue level form and function, and give rise to the complex, functional architectures observed in secondary lymphoid organs and disease specific TLT. These models permit *in silico* experimentation providing a unique platform driving further experimentation and assessing novel mechanistic targets and intervention strategies where *in vivo* observed heterogeneity can be replicated.

Alan Turing (of code breaking fame) in seminal early work in mathematical biology (Turing, 1952) noted that gastrulation, arose from symmetry breaking, this leads to fundamental insights and principles that drive modern mathematical and computational biology: the notion that chaotic, non-linear behaviour of individual biological processes, including the self-organisation of complex biological structures (e.g. TLT), can result in emergent properties that cannot be understood from consideration of each individual component in isolation. The development of models that capture the essential, emergent behaviour of specific biological processes, with extraneous components excluded, enables understanding of how complex molecular and cellular interactions govern complex, emergent biological processes and can therefore lead to new insights and quantitative predictions (Callard and Yates, 2005). Emergent properties in a TLT model would include stromal networks, lymphocyte organisation, migration and interactions with antigen presenting cells, and localised cytokine/chemokine production.

Application of model-driven experimentation to understand mechanisms of lymphoid tissue development and function.

179   Advances in computing resources and computational modelling technology has provided the

180   capacity to generate complex *in silico* models of lymphoid tissues that incorporate space, time

181   and cellular heterogeneity found in immune tissues including TLT.   Applying *in silico*

182   approaches to understand secondary lymphoid tissue formation and function requires the

183   integration of experimental data across cellular, molecular and tissue levels of organisation.

184   Ensuring that the biological processes are appropriately described requires a fine balance

185   between model abstraction and interpretation (quantitative and qualitative) of experimental

186   data. A number of different modelling approaches may be utilised (summarised in **Table 1**),

187   increasingly, integration of different mathematical/computational techniques into a hybrid

188   model is a common strategy to address the limitations of using each technique in isolation. This

189   approach also facilitates the consolidation of data across different levels of organisation

190   (molecular, cellular, tissue and patient) into a single multiscale model. For example, an agent-

191   based model can capture an individual cell, which in turn incorporates a differential equation-

192   based model capturing a 'lower-level' aspect of that individual's behaviour, such as surface

193   expression of a receptor. Adopting an *in silico* approach provides a platform that can provide

194   insights and generate predictions that can be verified *in vivo:* verification that can lead to

195   increased biological understanding and incrementally improved *in silico* models for further

196   experimentation. This iterative approach of combining *in vivo*, *in vitro* and *in silico* approaches

197   has been termed 'model-driven experimentation' (MDE)(Ganesan & Levchenko, 2012).

198

199   **Case Study 1: Insights from MDE to secondary lymphoid tissue formation:**

200

201   Peyer's patches (PP) are specialised secondary lymphoid tissues of the intestine that develop

202   during a fixed window in foetal development and have an essential role in maintaining

203   intestinal immunity. PP form stochastically along the mid-gut, with mice developing 8-12

204   patches, however, as the absence of or reduction in the number of PPs is observed in several

205   different gene knockouts, the molecular process which triggers patch formation was unclear

206   (Veiga-Fernandes et al., 2007). Using an MDE based approach had the potential to provide

207   new insight into how different signalling pathways (RET, chemokine receptors, cytokine

208   receptors, TNF superfamily, adhesion molecules) might integrate to induce PP development *in*

209   *silico* and to subsequently design key experiments to test hypotheses *in vivo*. PPSim is an agent

210   based Peyer's patch simulator that captures key processes during the 72-hour period of tissue

211   development in prenatal mice and replicates (statistically similar) emergent cell behaviours

212   found *in vivo,* specifically Populations of haematopoietic cells, known as Lymphoid Tissue

213   Initiator (LTin) and Lymphoid Tissue Inducer (LTi) cells, migrate into the developing gut, with

214   data from laboratory observations suggesting these cells follow a random motion. Both cell

215   populations express receptors for the adhesion molecule VCAM-1, expressed by stromal

216   Lymphoid Tissue Organizer (LTo) cells residing in the gut wall. (Alden et al., 2012; Patel et

217   al., 2012). In this computational model LTi and LTin are captured as individual entities that

218   migrate into the developing mid-gut serosa and undergo a random walk, interacting with their

219   localised simulated environment through signalling pathways including GDRFs/Ret signalling

220   pathways, adhesion molecules and chemokine receptors, as is observed *in vivo*. On ensuring

221   PPsim adequately represented individual cell responses, statistical analysis techniques,

222   specifically sensitivity analyses, were used to explore mechanisms driving prenatal lymphoid

223   organ formation (Alden et al., 2013; Butler et al., 2014). This exploration of the simulated

224   biological pathways revealed which pathways had significant impacts on simulated cell

225   behaviour at different time points during PP development. By examining correlations in the

226   level of activity of simulated pathways and cell behaviour, the hypothesis was derived that

227   contact between LTin and LTo cells that leads to the localised upregulation of VCAM-1 on

228   stromal cells was the key triggering event that determined the site of PP formation on the mid-

229   gut (Patel et al., 2012). Utilising this prediction, an *in vitro* assay imaging foetal mid-gut

230   explants incubated in the presence or absence of anti-VCAM-1 antibodies was developed.

231   Using this assay, it was verified that early upregulation of VCAM-1 was the triggering event

232   that was essential for the initiation of LTi & LTin cell clustering. The model simulation results,

233   supported by replicated experimentation and safety-critical systems-based fitness-for-purpose

234   argumentation that details the knowledge integration in model composition, provide evidence

235   that the simulation was fit for the purpose of aiding exploration of this specific research

236   question: understanding the triggering of lymphoid tissue development which was not possible

237   by conventional genetic approaches (Alden et al., 2015a; Alden et al., 2015b).

238

239   **Case Study 2: Applying MDE to understand germinal centre dynamics and function**

240

241   The GC reaction is a transient microenvironment in which affinity maturation occurs in

242   response to immunisation and infection bearing key similarities to TLT in its evolution in the

243   role of lymphocytes in inducing highly organised stromal networks, the essential role of TNF

244   superfamily members in regulating its induction and the induction of chemokine gradients (De

245   Silva and Klein, 2015; Victora and Mesin, 2014). However, in comparison to TLT, the GC is

246   a self-resolving tertiary lymphoid microenvironment. Recent technological advances,

247   particularly the advent of intravital multiphoton imaging including photo-activated fluorescent

248   proteins has led to the unprecedented availability of data on the dynamics B-cell migration and

249   selection (Allen et al., 2007; Schwickert et al., 2007; Shulman et al., 2013, 2014). However,

250   imaging datasets provide a narrow window of insight into a process that occurs over a timescale

251   of days and weeks. Furthermore, as imaging techniques are optimised for a given time and

252   length scale, they are limited in their ability to link molecular, cellular and tissue level

253   processes. This has made the interpretation of imaging datasets in the context of the wider

254   literature challenging. To address this issue modelling approaches have been used to test the

255   validity of different hypotheses for mechanisms controlling B-cell migration and selection

256   within the GC (Chan et al., 2013; Figge et al., 2008; Meyer-Hermann, 2006; Meyer-Hermann

257   et al., 2012).

258   With respect to the germinal centre, model-derived insights have proved useful not only in the

259   analysis of existing datasets but also as a driver for further experimentation. Specifically, an

260   MDE approach to examine the effects of antibody-feedback on the process of affinity

261   maturation (Zhang et al., 2013). Analysis of an *in silico* GC reaction yielded the prediction

262   that GC B-cells, which require antigen on FDCs for positive selection, were competing for

263   antigen by early low-affinity antibodies. Only higher affinity B-cells were able to outcompete

264   for antigen to receive the necessary survival signals. To experimentally validate this prediction,

265   the authors manipulated the GC response with monoclonal antibodies of defined affinities and

266   were able to confirm that antibody feedback provides a dynamic selection threshold to

267   maximise Ig affinities (Zhang et al., 2013). A similar approach was employed to investigate

268   the role of Toll-like receptor 4 (TLR4) on the GC where an iterative cycle of *in silico* and *in*

269   *vivo* experimentation dissected the importance of TLR4 signalling on the maturation of

270   Follicular Dendritic Cells, key regulators of B-cell selection in the light zone of the GC (Garin

271   et al., 2010). Both of these MDE examples highlight the use of *in silico* experimentation as a

272   means of refining the use of experimental animals and available resources through the

273   identification of key time-points and conditions to test *in vivo*. These case studies together

274   provide example of how theoretical models can consolidate data from different sources as a

275   platform for the development novel hypotheses and a driver for further experimentation.

276

Perspective on MDE as applied to tertiary lymphoid tissue formation, function and therapeutic resolution.

When computational modelling is combined with the knowledge that can be derived from next generation imaging, multi-dimensional cytometry and gene expression analysis of human TLT pathology, MDE has the potential to provide novel insights to key questions on molecular and cellular mechanisms involved in TLT formation, maintenance and function similar to its capacity to impact on our understanding of lymphoid stromal network and granuloma dynamics (**Table 2**)(Kislitsyn, A et al., 2015; Novkovic M et al., 2016; Warsinke et al., 2016; Marino et al., 2016). One of the key advantages of applying multi-scale modelling is it permits capture of a wide range of different phenomena that occur on different orders of magnitude in terms of time and length scales that are critical in the stochastic processes involved in TLT induction. These include different cell types, states and interactions, inflammatory molecules, extracellular matrix, adhesion molecules and chemotactic signals all in the context of an evolving tissue microenvironment. Developing *in silico* models permits temporal inhibition of different signalling pathways and cellular depletions during different stages of TLT pathology using statistical tools (**Figure 1**). This permits identification of key pathways that could be targeted to induce resolution of pre-existing TLT rather than inhibiting its formation as has been used to make in silico predictions for the treatment of tuberculosis (Pienarr et al., 2015). A large number of novel antibody therapies, biologics and small molecular inhibitors have been developed to target immune function for the treatment of immune mediated inflammatory diseases. These therapies are unlikely to show maximal efficacy against existing tissue pathology when used as mono-therapies, rather it is more likely that use of therapeutic combinations that is most likely to show clinical efficacy. The clinical challenge is that there are already over 20,000 possible different combinations using existing therapeutics that would

302   need to be trialled to find optimal targeting strategy to resolve TLT pathology. Thus MDE

303   based approaches provide a rational approach to identify novel combination therapeutic

304   regimes that have a best potential in clinical trials.

305

306   Although the adoption of MDE has only recently started to impact on immunology research, it

307   is starting to have a very significant impact on other areas of biology. We propose that the

308   increased accessibility of computational models, high-performance computing resources, the

309   increased familiarity and understanding of simulations as tools to understand immune function

310   and the capacity to apply *in silico* approaches to identify potential therapeutic approaches and

311   disease biomarkers will accelerate the application of MDE as a methodology understand and

312   target disease resolution.

References:

Alden, K., Andrews, P.S., Veiga-Fernandes, H., Timmis, J., Coles, M.C. (2015a), Utilising a Simulation Platform to Understand the Effect of Domain Model Assumptions. Natural Computing, doi: 10.1007/s11047-014-9428-7

Alden K, Andrews PS, Polack FA, Veiga-Fernandes H, Coles MC, Timmis J. (2015b) Using argument notation to engineer biological simulations with increased confidence. J R Soc Interface. 6;12(104):20141059.

Alden, k., Timmis, J., Andrews, P.S., Veiga-Fernandes, H., Coles, M., (2012) Pairing experimentation and computational modelling to understand the role of tissue inducer cells in the development of lymphoid organs. Frontiers in Immunology. Vol 3. DOI:10.3389/fimmu.2012.00172.

Alden K, Read, M., Timmis, J., Andrews, P., Veiga-Fernades, H., Coles, M. (2013) Spartan: A Comprehensive Tool for Understanding Uncertainty in Simulations of Biological Systems. PLOS Computational Biology, Feb;9(2):e1002916. doi: 10.1371/journal.pcbi.1002916.

Allen, C.D.C., Okada, T., Tang, H.L., and Cyster, J.G. (2007). Imaging of Germinal Center Selection Events During Affinity Maturation. Science 315, 528–531.

Bagabir, R., Byers, R.J., Chaudhry, I.H., Müller, W., Paus, R., Bayat, A., (2012) Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. Br J Dermatol 167(5):1053-66.

Bolus, W.R., Gutierrez, D.A., Kennedy, A.J., Anderson-Baucum, E.K., Hasty, A.H. (2015) CCR2 deficiency leads to increased eosinophils, alternative macrophage activation, and type 2 cytokine expression in adipose tissue. J Leukoc Biol. 98(4):467-77.

Bombardieri, M., Barone, F., Lucchesi, D., Nayar, S., van den Berg, W.B., Proctor, G., Buckley, C.D., Pitzalis, C., (2012) Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J Immunol. 189(7):3767-76.

Butler, J. A., Alden, K., Veiga Fernandex, H., Timmis, J., & Coles, M. Novel approaches to the visualization and quantification of biological simulations by emulating experimental techniques. ALIFE 14: Proceedings of the Fourteenth International Conference on the Synthesis and Simulation of Living Systems, MIT Press, 14, 614-621. (2014) doi:10.7551/978-0-262-32621-6-ch099

Callard, R.E., & Yates, A.J. (2005). Immunology and mathematics: crossing the divide. Immunology, 115(1), 21-33

Chan, C., Billard, M., Ramirez, S.A., Schmidl, H., Monson, E., and Kepler, T.B. (2013). A model for migratory B cell oscillations from receptor down-regulation induced by external chemokine fields. Bull. Math. Biol. 75, 185–205.

360 Cosgrove, J., Butler, J., Alden, K., Read, M., Kumar, V., Cucurull-Sanchez, L., Timmis, J,
361 Coles, M. (2015). Agent-Based Modeling in Systems Pharmacology.CPT: pharmacometrics
362 & systems pharmacology, 4(11), 615-629.

364 De Silva, N.S., & Klein, U. (2015). Dynamics of B cells in germinal centres. Nat. Rev.
365 Immunol. 15, 137–148.

367 Dieu-Nosjean, M.C., Giraldo, N.A., Kaplon, H., Germain, C., Fridman, W.H., Sautès-
368 Fridman C., (2016) Tertiary lymphoid structures, drivers of the anti-tumor responses in
369 human cancers. Immunol Rev. 271(1):260-75.

371 Figge, M.T., Garin, A., Gunzer, M., Kosco-Vilbois, M., Toellner, K.-M., and Meyer-
372 Hermann, M., (2008). Deriving a germinal center lymphocyte migration model from two-
373 photon data. J. Exp. Med. 205, 3019–3029.

375 Ganesan, A., Levchenko A. (2012) Principles of model building: an experimentation-aided
376 approach to development of models for signaling networks. Methods Cell Biol. 110 :1-17.

378 Garin, A., Meyer-Hermann, M., Contie, M., Figge, M.T., Buatois, V., Gunzer, M., Toellner,
379 K.-M., Elson, G., and Kosco-Vilbois, M.H. (2010). Toll-like Receptor 4 Signaling by
380 Follicular Dendritic Cells Is Pivotal for Germinal Center Onset and Affinity Maturation.
381 Immunity 33, 84–95.

383 Guilloton, F., Caron, G., Ménard, C., Pangault, C., Amé-Thomas, P., Dulong, J., De Vos, J.,
384 Rossille, D., Henry, C., Lamy, T., Fouquet, O., Fest, T., Tarte, K. (2012) Mesenchymal
385 stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent
386 recruitment and polarization of monocytes. Blood. 119(11):2556-67.

388 Jarjour, M., Jorquera, A., Mondor, I., Wienert, S., Narang, P., Coles, M., Klauschen, F.,
389 Bajenoff, M., Fate mapping reveals Origin and Dynamics of lymph node Follicular Dendritic
390 Cells, Journal of Experimental Medicine, 211(6):1109-22, 2014.

392 Junt, T., Scandella, E., Ludewig, B., Form follows function: lymphoid tissue
393 microarchitecture in antimicrobial immune defence Nature Reviews Immunology 8, 764-775
394 (2008) doi:10.1038/nri2414

396 Kaye, P.M., Beattie, L. (2016) Lessons from other diseases: granulomatous inflammation in
397 leishmaniasis. Semin Immunopathol. 38(2):249-60.

399 Kislitsyn, A., Savinkov, R., Novkovic, M., Onder, L., & Bocharov, G. (2015). Computational
400 Approach to 3D Modeling of the Lymph Node Geometry. Computation, 3(2), 222-234.

402 Marino, S., Gideon, H.P., Gong, C., Mankad, S., McCrone, J.T., Lin, P.L., Linderman, J.J.,
403 Flynn, J.L., Kirschner, D.E., (2016) Computational and Empirical Studies Predict
404 Mycobacterium tuberculosis-Specific T Cells as a Biomarker for Infection Outcome. PLoS
405 Comput Biol. 11;12(4):e1004804.

407 Meyer-Hermann, M.E. (2006). An analysis of B cell selection mechanisms in germinal
408 centers. Math. Med. Biol. 23, 255–277.
409

410 Meyer-Hermann, M., Mohr, E., Pelletier, N., Zhang, Y., Victora, G.D., and Toellner, K.-M.
411 (2012). A Theory of Germinal Center B Cell Selection, Division, and Exit. Cell Rep. 2, 162–
412 174.
413
414 Mitta,l S., Revell, M., Barone, F., Hardie, D.L., Matharu, G.S., Davenport ,A.J., Martin, R.A.,
415 Grant, M., Mosselmans, F., Pynsent, P., Sumathi, V.P., Addison, O., Revell, P.A., Buckley,
416 C.D. (2013) Lymphoid aggregates that resemble tertiary lymphoid organs define a specific
417 pathological subset in metal-on-metal hip replacements. PLoS One, 8(5):e63470.
418
419 Mowat, A.,& Agace W. (2014) Regional specialization within the intestinal immune system,
420 Nature Reviews Immunology 14, 667–685.
421
422 De Silva S.D., & Klein, U., (2015) Dynamics of B cells in germinal centres. Nature Reviews
423 Immunology 15, 137–148.
424
425 Novkovic, M., Onder, L., Cupovic, J., Abe, J., Bomze, D., Cremasco, V., Scandella, E., Stein,
426 J.V., Bocharov, G., Turley, S.J., Ludewig, B. (2016) Topological Small-World Organization
427 of the Fibroblastic Reticular Cell Network Determines Lymph Node Functionality. PLoS Biol.
428 14(7):e1002515.
429
430 Patel, N. Harker, L. Moreira-Santos, M. Ferreira, K. Alden, J. Timmis, K. Foster, A.
431 Garefalaki, P. Pachnis, P. Andrews, H. Enomoto, J. Milbrandt, V. Pachnis, M. C. Coles, D.
432 Kioussis, H. Veiga-Fernandes. (2012) Differential RET Signaling Pathways Drive
433 Development of the Enteric Lymphoid and Nervous Systems. Science Signalling 5: 235.
434
435 Pienaar, E., Dartois, V., Linderman, J.J., Kirschner, D.E. (20150) In silico evaluation and
436 exploration of antibiotic tuberculosis treatment regimens. BMC Syst Biol. 9: 79.
437
438 Sandor, M., Weinstock, J.V., Wynn, T.A., (2003) Granulomas in schistosome and
439 mycobacterial infections: a model of local immune responses. Trends Immunol. 24(1):44-52.
440
441 Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjogren's syndrome: a twelve-week
442 randomized, doubleblind, placebo-controlled pilot clinical trial. Arthritis Rheum
443 2004;50:2240–5.
444
445 Schwickert, T.A., Lindquist, R.L., Shakhar, G., Livshits, G., Skokos, D., Kosco-Vilbois,
446 M.H., Dustin, M.L., and Nussenzweig, M.C. (2007). In vivo imaging of germinal centres
447 reveals a dynamic open structure. Nature 446, 83–87.
448
449 Shulman, Z., Gitlin, A.D., Targ, S., Jankovic, M., Pasqual, G., Nussenzweig, M.C., and
450 Victora, G.D. (2013). T follicular helper cell dynamics in germinal centers. Science 341,
451 673–677.
452
453 Shulman, Z., Gitlin, A.D., Weinstein, J.S., Lainez, B., Esplugues, E., Flavell, R.A., Craft,
454 J.E., and Nussenzweig, M.C. (2014). Dynamic signaling by T follicular helper cells during
455 germinal center B cell selection. Science 345, 1058–1062.
456
457 Turing, A.M. (1952). The chemical basis of morphogenesis. Philosophical Transactions of
458 the Royal Society of London B: Biological Sciences, 237(641), 37-72.
459

460   van de Pavert, SA. & Mebius, R. (2010) New insights into the development of lymphoid
461   tissues, Nature Reviews Immunology 10, 664-674.
462
463   Victora, G.D., and Mesin, L. (2014). Clonal and cellular dynamics in germinal centers. Curr.
464   Opin. Immunol. 28, 90–96.
465
466   Veiga-Fernandes, H., Coles, M.C., Foster, K.E., Patel, A., Williams, A., Natarajan, D.,
467   Barlow, A., Pachnis, V., Kioussis, D, (2007) Tyrosine kinase receptor Ret is a key regulator
468   in Peyer's Patch organogenesis. Nature, vol 446(7135) 547-51.
469
470   Warsinske, H.C., Wheaton, A.K., Kim, K.K., Linderman, J.J., Moore, B.B., Kirschner, D.E.
471   (2016).   Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and
472   Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis. Front Pharmacol. 23;7:183.
473
474   Zhang, Y., Meyer-Hermann, M., George, L.A., Figge, M.T., Khan, M., Goodall, M., Young,
475   S.P., Reynolds, A., Falciani, F., Waisman, A., et al. (2013). Germinal center B cells govern
476   their own fate via antibody feedback. J. Exp. Med. 210, 457–464.
477
478   Zhang Y., Garcia-Ibanez L., Toellner KM. (2016) Regulation of germinal center B-cell
479   differentiation. Immunol Rev., 270(1):8-19.
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506

Table 1: Mathematical and Computational Techniques for Modelling Immune Processes

Technique	Description	Comments
ODE	Ordinary Differential Equations: Describe the rate of change with respect to one other variable (e.g. population change over time, t).	Commonly used technique that can be used to quantify changes in population size over time.
PDE	Partial Differential Equations: Describe rate of change of a function of more than one variable with respect to one of those variables (e.g. motion through space x,y,z as a function of time t).	Often used to describe changes occurring over both time and multiple spatial dimensions.
Monte Carlo	Statistical random sampling method where outcomes are determined at random from input probability distribution functions.	Stochastic technique to model deterministic processes, very frequently integrated within ABM, CPM and other stochastic modelling approaches.
Petri Nets	Graph based model describing network of events or 'transitions' that occur depending on given conditions or 'places'; a stochastic methodology.	Computationally efficient, can be effectively defined using SBML2. Capturing explicit spatial representation can be difficult.
ABMs	Agent Based Models are composed of individual entities specified as agents which exist independently in a well-defined state: a set of attributes at a specific point in (e.g.) time and space, with state-transitions governed by a rule-set, often described in terms of Finite State Machines and other diagrammatic constructs using the UML (Unified Modelling Language).	There are a number of methodologies to generate ABMs. There are tools with user interfaces for constructing simpler lattice-based ABMS, or 'unconstrained' models manually coded as software in languages such as Java and C++.
(Extended) Cellular Potts Modelling	A lattice based modelling technique for simulating the collective behaviour of cells. A cell is defined as a set of pixels within a lattice (sharing a 'spin state'), and is updated pixel-by-pixel according to a mathematical function which incorporates cell volume, and surface/adhesion energies.	Similar to an ABM, but relies on effective energy functions (the Hamiltonian) to describe cellular adhesion, signalling, motility and other physical phenomena.
Hybridised Models	Bringing together a range of different techniques generally within the context of an ABM or CPM, incorporating differential equations and a variety of other mathematical and computational techniques to effectively capture phenomena occurring over different spatiotemporal scales (e.g. intracellular activity)	Can take advantage of different modelling techniques, particularly applicable where there are multiple processes occurring in different scales of time and space.

508 **Table 2:** Key questions on TLT formation and maintenance that can be address in hybridised

509 TLT models

Formation
What are the minimum cellular requirements to initiate TLT formation? Is this driven by different types of stroma, lymphocytes, dendritic cells or tissue resident macrophage?
What is the relative importance of inflammation and antigen in TLT induction? Is autoantigen required for induction or just an outcome of the pathology?
What is the role of different cytokines and chemotactic signals on TLT formation?
Maintenance
What is the relative role of inflammatory cytokines, lymphocyte – stromal cross talk, immune cell entry, cell death, antigenic stimulation on TLT maintenance?
What are the key signalling pathways required to maintain TLT once it has formed? Can these pathways be targeted to induce TLT resolution?
Can TLT self-resolve in humans? If so what is the balance between new TLT induction and resolution of existing structures?

510
511

Model-Driven Experimentation (MDE)

Experimentation
in vivo, in vitro

Simulation
in silico

Hypothesis Testing

Hypothesis Generation

Experimental Evidence

Mechanistic Model

Candidate Therapy

Pharmacologic Assessment
PK-PD
Toxicology
Efficacy

Extended Domain Knowledge

512
513
514
515 **Figure 1:** Application of Model-driven Experimentation to develop new mechanistic
516 understanding of TLT formation and maintenance permitting identification of novel
517 therapeutic approaches to resolve localised TLT pathology.

Figure 01.JPEG

Model-Driven Experimentation (MDE)